HORIZON EUROPE
Europeo
Specific Challenge:In Alzheimer’s Disease (AD) extracellular depositions of amyloid beta peptides (plaques) and intracellular filamentous inclusions of tau (tangles) constitutes a hallmark of the disease. In Parkinson’s Disease (PD) the neuropathology is defined by intracellular inclusions of alpha-synuclein (Lewy bodies and Lewy neurites). Recently, new scientific opportunities to identify druggable targets have arisen based on the spreading and seeding hypothesis of tau and alpha-synuclein protein as prion-like proteins. This hypothesis allows setup of in vitro and in vivo models based on tau or alpha-synuclein pathological material isolated from patients, animal models or recombinant fibrils seeded into cells or animals and with a resulting defined mechanistic readout (spreading or seeding). Thus, it is envisioned that these models may be used in a screening setup to identify new targets and later validate their druggability. Advancing and focusing the research discoveries to identify drug targets related to Alzheimer’s and Parkinson’s disease requires multidisciplinary approaches including targets identification screens, tool compound development and validation in a wide range... ver más
Specific Challenge:In Alzheimer’s Disease (AD) extracellular depositions of amyloid beta peptides (plaques) and intracellular filamentous inclusions of tau (tangles) constitutes a hallmark of the disease. In Parkinson’s Disease (PD) the neuropathology is defined by intracellular inclusions of alpha-synuclein (Lewy bodies and Lewy neurites). Recently, new scientific opportunities to identify druggable targets have arisen based on the spreading and seeding hypothesis of tau and alpha-synuclein protein as prion-like proteins. This hypothesis allows setup of in vitro and in vivo models based on tau or alpha-synuclein pathological material isolated from patients, animal models or recombinant fibrils seeded into cells or animals and with a resulting defined mechanistic readout (spreading or seeding). Thus, it is envisioned that these models may be used in a screening setup to identify new targets and later validate their druggability. Advancing and focusing the research discoveries to identify drug targets related to Alzheimer’s and Parkinson’s disease requires multidisciplinary approaches including targets identification screens, tool compound development and validation in a wide range of experimental cell and animal disease models. The critical mass needed and availabilities of assay, models and reagents are only available through broad collaboration of public and private partners.
Scope:Our understanding of the molecular mechanisms involved in the spreading, uptake, seeding, aggregation, of tau and alpha-synuclein and their impact on cell homeostasis, release and toxicity is still very sparse, hence limiting effective intervention strategies. A key objective of the action will be to use the recent advances in setting up both in vitro and in vivo model systems for spreading and seeding processes. Genome-wide genetic screens and small molecule screens to identify targets and mechanism involved in these processes should be performed. Based on the key mechanisms identified in these screens, targets will be chosen for further validation of drugabbility and therapeutic potential in vitro and in vivo.
Expected Impact:Several outputs from the project may contribute to the R&D process of developing new therapies against PD and AD. Establishing a common preclinical platform of assays based on the hypothesis of turnover / aggregation / spreading of misfolded pathological proteins is important to reach a consensus of how new treatment principles can best be evaluated and substantiated. Such a platform can form the basis for identification of new druggable targets which would open up for development of new innovative treatments against PD and AD.
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
You can access the description of the different topics in the Call topics text.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section (page 78), as well as the following information :
List of countries and applicable rules for funding
Eligibility and admissibility conditions
Evaluation criteria and procedure, scoring and threshold : described in the IMI Manual for Submission, Evaluation and Grant award
Indicative timetable for evaluation and grant agreement
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
MI2 Coordination and Support Action (IMI2-CSA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
Please read carefully all provisions below before the preparation of your application.
You can access the description of the different topics in the Call topics text.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section (page 78), as well as the following information :
List of countries and applicable rules for funding
Eligibility and admissibility conditions
Evaluation criteria and procedure, scoring and threshold : described in the IMI Manual for Submission, Evaluation and Grant award
Indicative timetable for evaluation and grant agreement
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
MI2 Coordination and Support Action (IMI2-CSA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta